165 related articles for article (PubMed ID: 27398979)
1. Proteomics approaches in cervical cancer: focus on the discovery of biomarkers for diagnosis and drug treatment monitoring.
Kontostathi G; Zoidakis J; Anagnou NP; Pappa KI; Vlahou A; Makridakis M
Expert Rev Proteomics; 2016 Aug; 13(8):731-45. PubMed ID: 27398979
[TBL] [Abstract][Full Text] [Related]
2. Prior high-risk HPV testing and Pap test results for 427 invasive cervical cancers in China's largest CAP-certified laboratory.
Zheng B; Li Z; Griffith CC; Yan S; Chen C; Ding X; Liang X; Yang H; Zhao C
Cancer Cytopathol; 2015 Jul; 123(7):428-34. PubMed ID: 25954852
[TBL] [Abstract][Full Text] [Related]
3. Comparison of single-, double- and triple-combined testing, including Pap test, HPV DNA test and cervicography, as screening methods for the detection of uterine cervical cancer.
Kim JH; Kim IW; Kim YW; Park DC; Kim YW; Lee KH; Ahn TG; Han SJ; Ahn WS
Oncol Rep; 2013 Apr; 29(4):1645-51. PubMed ID: 23443346
[TBL] [Abstract][Full Text] [Related]
4. Elevated levels of tetraploid cervical cells in human papillomavirus-positive Papanicolaou smears diagnosed as atypical squamous cells of undetermined significance.
Olaharski AJ; Eastmond DA
Cancer; 2004 Jun; 102(3):192-9. PubMed ID: 15211479
[TBL] [Abstract][Full Text] [Related]
5. Human papilloma virus (HPV) molecular diagnostics.
Kroupis C; Vourlidis N
Clin Chem Lab Med; 2011 Nov; 49(11):1783-99. PubMed ID: 21875401
[TBL] [Abstract][Full Text] [Related]
6. Cervical screening test results associated with 265 histopathologic diagnoses of cervical glandular neoplasia.
Zhao C; Li Z; Austin RM
Am J Clin Pathol; 2013 Jul; 140(1):47-54. PubMed ID: 23765533
[TBL] [Abstract][Full Text] [Related]
7. Genetic and Environmental Factors in Invasive Cervical Cancer: Design and Methods of a Classical Twin Study.
Machalek DA; Wark JD; Tabrizi SN; Hopper JL; Bui M; Dite GS; Cornall AM; Pitts M; Gertig D; Erbas B; Garland SM
Twin Res Hum Genet; 2017 Feb; 20(1):10-18. PubMed ID: 27917752
[TBL] [Abstract][Full Text] [Related]
8. History of high-risk HPV and Pap test results in a large cohort of patients with invasive cervical carcinoma: experience from the largest women's hospital in China.
Tao X; Griffith CC; Zhou X; Wang Z; Yan Y; Li Z; Zhao C
Cancer Cytopathol; 2015 Jul; 123(7):421-7. PubMed ID: 25955972
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of human papillomavirus genotyping.
Choi YJ; Park JS
J Gynecol Oncol; 2016 Mar; 27(2):e21. PubMed ID: 26768784
[TBL] [Abstract][Full Text] [Related]
10. Downregulation of tumor suppressor gene PML in uterine cervical carcinogenesis: impact of human papillomavirus infection (HPV).
Singh N; Sobti RC; Suri V; Nijhawan R; Sharma S; Das BC; Bharadwaj M; Hussain S
Gynecol Oncol; 2013 Mar; 128(3):420-6. PubMed ID: 23220564
[TBL] [Abstract][Full Text] [Related]
11. Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Russian Federation, the Western countries of the former Soviet Union, Caucasus region and Central Asia.
Rogovskaya SI; Shabalova IP; Mikheeva IV; Minkina GN; Podzolkova NM; Shipulina OY; Sultanov SN; Kosenko IA; Brotons M; Buttmann N; Dartell M; Arbyn M; Syrjänen S; Poljak M
Vaccine; 2013 Dec; 31 Suppl 7():H46-58. PubMed ID: 24332297
[TBL] [Abstract][Full Text] [Related]
12. Human papillomavirus: science and technologies for the elimination of cervical cancer.
Bosch FX
Expert Opin Pharmacother; 2011 Oct; 12(14):2189-204. PubMed ID: 21756205
[TBL] [Abstract][Full Text] [Related]
13. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries.
Cuzick J; Arbyn M; Sankaranarayanan R; Tsu V; Ronco G; Mayrand MH; Dillner J; Meijer CJ
Vaccine; 2008 Aug; 26 Suppl 10():K29-41. PubMed ID: 18847555
[TBL] [Abstract][Full Text] [Related]
14. Screening test results associated with cancer diagnoses in 287 women with cervical squamous cell carcinoma.
Li Z; Austin RM; Guo M; Zhao C
Arch Pathol Lab Med; 2012 Dec; 136(12):1533-40. PubMed ID: 22900617
[TBL] [Abstract][Full Text] [Related]
15. Comparison of cervical cancer screening results among 256,648 women in multiple clinical practices.
Blatt AJ; Kennedy R; Luff RD; Austin RM; Rabin DS
Cancer Cytopathol; 2015 May; 123(5):282-8. PubMed ID: 25864682
[TBL] [Abstract][Full Text] [Related]
16. Reduced rate of human papillomavirus infection and genetic overtransmission of TP53 72C polymorphic variant lower cervical cancer incidence.
Alsbeih GA; Al-Harbi NM; Bin Judia SS; Khoja HA; Shoukri MM; Tulbah AM
Cancer; 2017 Jul; 123(13):2459-2466. PubMed ID: 28393355
[TBL] [Abstract][Full Text] [Related]
17. Randomized controlled trial of human papillomavirus testing versus Pap cytology in the primary screening for cervical cancer precursors: design, methods and preliminary accrual results of the Canadian cervical cancer screening trial (CCCaST).
Mayrand MH; Duarte-Franco E; Coutlée F; Rodrigues I; Walter SD; Ratnam S; Franco EL;
Int J Cancer; 2006 Aug; 119(3):615-23. PubMed ID: 16572425
[TBL] [Abstract][Full Text] [Related]
18. Cervical cancer: Biomarkers for diagnosis and treatment.
Dasari S; Wudayagiri R; Valluru L
Clin Chim Acta; 2015 May; 445():7-11. PubMed ID: 25773118
[TBL] [Abstract][Full Text] [Related]
19. Association of IL-10 GTC haplotype with serum level and HPV infection in the development of cervical carcinoma.
Singhal P; Kumar A; Bharadwaj S; Hussain S; Bharadwaj M
Tumour Biol; 2015 Apr; 36(4):2287-98. PubMed ID: 25412954
[TBL] [Abstract][Full Text] [Related]
20. Unmet clinical needs in cervical cancer screening.
Rao J; Escobar-Hoyos L; Shroyer KR
MLO Med Lab Obs; 2016 Jan; 48(1):8, 10, 14; quiz 15. PubMed ID: 26887092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
